Valuation: Avicanna Inc.

Market Cap 1.55Cr 1.09Cr 95.44L 88L 81.52L 103.36Cr 1.57Cr 11Cr 4.1Cr 51Cr 4.09Cr 4Cr 176.6Cr P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 1.52Cr 1.07Cr 93.71L 86.4L 80.04L 101.48Cr 1.54Cr 10Cr 4.02Cr 50Cr 4.01Cr 3.92Cr 173.4Cr EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day-1.45%
1 week-10.46%
Current month-10.46%
1 month-1.93%
3 months-30.21%
6 months-49.19%
Current year-49.85%
1 week 0.08
Extreme 0.0792
0.1
1 month 0.08
Extreme 0.075
0.11
Current year 0.08
Extreme 0.075
0.18
1 year 0.08
Extreme 0.075
0.24
3 years 0.08
Extreme 0.075
0.53
5 years 0.08
Extreme 0.075
1.24
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%-10.46% - - 1.09Cr
-1.03%+5.24%+2.94%+9.41% 5.03TCr
+0.25%+1.70%+419.39%+621.71% 4.04TCr
+1.10%+7.77%+28.18%-3.96% 3.44TCr
-0.16%+8.12%+27.85%+62.55% 3.44TCr
+1.31%-0.56%+5.12%+33.90% 2.63TCr
-0.35%+0.09% - - 1.66TCr
-3.33%+3.15%+71.30%+131.94% 1.61TCr
+0.32%+0.53%+14.33%+21.47% 1.37TCr
+3.79%+8.88%+106.63%+106.63% 1.37TCr
Average +0.02%+4.45%+84.47%+122.96% 2.73TCr
Weighted average by Cap. +0.05%+5.02%+95.76%+141.20%

Financials

2024 2025
Net sales 2.55Cr 1.79Cr 1.57Cr 1.45Cr 1.34Cr 170.27Cr 2.59Cr 17Cr 6.75Cr 84Cr 6.73Cr 6.58Cr 290.94Cr 2.55Cr 1.79Cr 1.57Cr 1.45Cr 1.34Cr 170.4Cr 2.59Cr 17Cr 6.75Cr 84Cr 6.74Cr 6.59Cr 291.16Cr
Net income -36.18L -25.46L -22.34L -20.6L -19.08L -24Cr -36.78L -2.47Cr -95.88L -12Cr -95.64L -93.57L -41Cr -27.59L -19.42L -17.04L -15.71L -14.55L -18Cr -28.05L -1.88Cr -73.13L -9.1Cr -72.95L -71.37L -32Cr
Net Debt -3L -2L -2L -2L -2L -2.27Cr -3L -23.12L -9L -1.12Cr -9L -9L -3.87Cr -3L -2L -2L -2L -1L -1.88Cr -3L -19.15L -7L -92.58L -7L -7L -3.21Cr
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
07/26/07 $0.0813 -1.45% 1,25,700
06/26/06 $0.0825 -7.20% 2,48,000
02/26/02 $0.0889 -13.27% 66,300
01/26/01 $0.1025 +12.89% 2,733
30/26/30 $0.0908 -4.92% 37,600